Treatment of cirrhotic ascites
- PMID: 17715638
Treatment of cirrhotic ascites
Abstract
Cirrhosis is the most common cause of ascites and accounts for almost 85% of all cases. It is the most common complication of cirrhosis, after development of ascites only 50% of patients will survive for 2 to 5 years. Successful treatment is dependent on accurate diagnosis of the cause of ascites. Because sodium and water retention is the basic abnormality leading to ascites formation, restriction of sodium intake and enhancing sodium excretion is the mainstay of the treatment of ascites. Patients with cirrhosis and ascites must limit sodium intake to 2 gram per day. Enhancement of sodium excretion can be accomplished by usage of oral diuretics. The recommended initial dose is spironolactone 100-200 mg/d and furosemide 20-40 mg/d. usual maximum doses are 400 mg/d of spironolactone and 160 mg/d of furosemide. The recommended weight loss in patients without peripheral edema is 300 to 500 g/d. There is no limit to the daily weight loss of patients who have edema. About 90% of patients respond well to medical therapy for ascites. Refractory ascites is defined as fluid overload that is unresponsive to sodium restricted diet and high dose diuretic treatment (diuretic resistant) or when there is an inability to reach maximal dose of diuretics because of adverse effects (diuretic-intractable). It has a poor prognosis. Treatment options for patients with refractory ascites are serial therapeutic paracentesis, transjugular intrahepatic stent-shunt (TIPS) or peritoneovenous shunt and liver transplantation. TIPS should be considered in patients who repeatedly fail large-volume paracentesis and have relatively preserved liver functions. Liver transplantation is the only modality that is associated with improved survival.
Similar articles
-
Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis.Liver Int. 2010 Aug;30(7):937-47. doi: 10.1111/j.1478-3231.2010.02272.x. Epub 2010 May 21. Liver Int. 2010. PMID: 20492521 Review.
-
Treatment of ascites in cirrhosis. Diuretics, peritoneovenous shunt, and large-volume paracentesis.Gastroenterol Clin North Am. 1992 Mar;21(1):237-56. Gastroenterol Clin North Am. 1992. PMID: 1568775 Review.
-
Management of refractory ascites.Am J Ther. 2012 Mar;19(2):121-32. doi: 10.1097/MJT.0b013e3181ff7a8b. Am J Ther. 2012. PMID: 21192246 Review.
-
Management of ascites in patients with cirrhosis. What to do when diuretics fail.Postgrad Med. 1992 Dec;92(8):155-8, 161-6. doi: 10.1080/00325481.1992.11701557. Postgrad Med. 1992. PMID: 1454665 Review.
-
[How I treat ... ascites].Rev Med Liege. 2001 Dec;56(12):809-15. Rev Med Liege. 2001. PMID: 11820032 French.
Cited by
-
Beyond Gender Identity Disorder Diagnoses Codes: An Examination of Additional Methods to Identify Transgender Individuals in Administrative Databases.Med Care. 2020 Oct;58(10):903-911. doi: 10.1097/MLR.0000000000001362. Med Care. 2020. PMID: 32925416 Free PMC article.
-
Sodium restriction in patients with cirrhotic ascites: a protocol for a systematic review.Syst Rev. 2016 May 10;5:78. doi: 10.1186/s13643-016-0250-4. Syst Rev. 2016. PMID: 27160239 Free PMC article.
-
Dose optimization of non-selective beta blockers among esophageal varices patients at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia: a hospital-based cross-sectional study.BMC Gastroenterol. 2025 Feb 21;25(1):100. doi: 10.1186/s12876-025-03708-2. BMC Gastroenterol. 2025. PMID: 39984863 Free PMC article.
-
Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma.World J Gastroenterol. 2017 Aug 7;23(29):5379-5385. doi: 10.3748/wjg.v23.i29.5379. World J Gastroenterol. 2017. PMID: 28839438 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical